The U.K. government issued a new warning aimed at the misuse of GLP-1 therapies by those who don’t qualify for the meds but are instead using them for quick-fix weight loss.

A turbulent series of events around the supply of Eli Lilly’s blockbuster weight loss treatment has raised concerns around ...

Lots of money is pouring into two critical races for Washington's legislature this year — and some big name companies are ...

ResMed beat Wall Street estimates for quarterly profit on Thursday, driven by strong demand for its devices used for sleep ...

Semaglutide (Ozempic) was tied to a reduced risk of Alzheimer's disease diagnoses in people with type 2 diabetes, ...

Course instructors are Ignition Coaching's founder, Kully Jaswal, alongside Executive Coach, Wagner Denuzzo, author of Leading to Succeed: Essential Skills for The New Workplace . "After coaching over ...

Though Lilly has been in the spotlight for the success of its GLP-1 drugs, the pharma giant has also been investing in a corporate brand campaign to boost its overall reputation.

The company is suing some online vendors and medical spas for selling copycats of a weight loss and diabetes drug.

Eli Lilly (LLY) is reportedly preparing to launch Mounjaro in Denmark, the home country of its leading rival in the ...

Advocates for diabetes patients who need insulin to survive worry the nation's supply is unreliable. Meanwhile, use of ...

A recent investigation by The New York Times revealed that two pharmaceutical companies, Eisai and Eli Lilly, withheld critical genetic risk information from volunteers during clinical trials for ...